209 related articles for article (PubMed ID: 35185894)
21. Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.
Nakazawa T; Hidaka H; Takada J; Okuwaki Y; Tanaka Y; Watanabe M; Shibuya A; Minamino T; Kokubu S; Koizumi W
Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):683-9. PubMed ID: 23395995
[TBL] [Abstract][Full Text] [Related]
22. Serum C-reactive protein levels predict survival in hepatocellular carcinoma.
Nagaoka S; Yoshida T; Akiyoshi J; Akiba J; Torimura T; Adachi H; Kurogi J; Tajiri N; Inoue K; Niizeki T; Koga H; Imaizumi T; Kojiro M; Sata M
Liver Int; 2007 Oct; 27(8):1091-7. PubMed ID: 17845537
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization.
Lee YK; Kim SU; Kim DY; Ahn SH; Lee KH; Lee DY; Han KH; Chon CY; Park JY
BMC Cancer; 2013 Jan; 13():5. PubMed ID: 23282286
[TBL] [Abstract][Full Text] [Related]
24. High level of intercellular adhesion molecule-1 affects prognosis of patients with hepatocellular carcinoma.
Zhu PP; Yuan SG; Liao Y; Qin LL; Liao WJ
World J Gastroenterol; 2015 Jun; 21(23):7254-63. PubMed ID: 26109813
[TBL] [Abstract][Full Text] [Related]
25. C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation.
Meischl T; Rasoul-Rockenschaub S; Györi G; Sieghart W; Reiberger T; Trauner M; Soliman T; Berlakovich G; Pinter M
PLoS One; 2019; 14(5):e0216677. PubMed ID: 31141535
[TBL] [Abstract][Full Text] [Related]
26. Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study.
Chen SC; Huang YH; Chen MH; Hung YP; Lee RC; Shao YY; Chao Y
BMC Cancer; 2022 Jan; 22(1):55. PubMed ID: 35016637
[TBL] [Abstract][Full Text] [Related]
27. Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis.
Tsai HM; Han MZ; Lin YJ; Chang TT; Chen CY; Cheng PN; Chuang CH; Wu IC; Chen PJ; Kang JW; Chiu YC; Chiu HC; Chien SC; Kuo HY
Cancer Immunol Immunother; 2021 Jul; 70(7):1929-1937. PubMed ID: 33409737
[TBL] [Abstract][Full Text] [Related]
28. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis.
Memon K; Kulik L; Lewandowski RJ; Wang E; Ryu RK; Riaz A; Nikolaidis P; Miller FH; Yaghmai V; Baker T; Abecassis M; Benson AB; Mulcahy MF; Omary RA; Salem R
J Hepatol; 2012 May; 56(5):1112-1120. PubMed ID: 22245905
[TBL] [Abstract][Full Text] [Related]
29. Comparison of α-Fetoprotein Criteria and Modified Response Evaluation Criteria in Solid Tumors for the Prediction of Overall Survival of Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization.
Zhang YQ; Jiang LJ; Wen J; Liu DM; Huang GH; Wang Y; Fan WZ; Li JP
J Vasc Interv Radiol; 2018 Dec; 29(12):1654-1661. PubMed ID: 30396842
[TBL] [Abstract][Full Text] [Related]
30. Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors.
Zhang R; Zhao H; Wang P; Guo Z; Liu C; Qu Z
BMC Cancer; 2023 Dec; 23(1):1181. PubMed ID: 38041022
[TBL] [Abstract][Full Text] [Related]
31. Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma.
Sun Y; Zhu S; Wu Z; Huang Y; Liu C; Tang S; Wei L
Oncotarget; 2017 Apr; 8(14):23427-23435. PubMed ID: 28178643
[TBL] [Abstract][Full Text] [Related]
32. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma.
Lee S; Rhim H; Kim YS; Kang TW; Song KD
Liver Int; 2016 Apr; 36(4):580-7. PubMed ID: 26503910
[TBL] [Abstract][Full Text] [Related]
33. C-reactive protein is a biomarker of AFP-negative HBV-related hepatocellular carcinoma.
She S; Xiang Y; Yang M; Ding X; Liu X; Ma L; Liu Q; Liu B; Lu Z; Li S; Liu Y; Ran X; Xu X; Hu H; Hu P; Zhang D; Ren H; Yang Y
Int J Oncol; 2015 Aug; 47(2):543-54. PubMed ID: 26058824
[TBL] [Abstract][Full Text] [Related]
34. High preoparative levels of serum periostin are associated with poor prognosis in patients with hepatocellular carcinoma after hepatectomy.
Lv Y; Wang W; Jia WD; Sun QK; Huang M; Zhou HC; Xia HH; Liu WB; Chen H; Sun SN; Xu GL
Eur J Surg Oncol; 2013 Oct; 39(10):1129-35. PubMed ID: 23916473
[TBL] [Abstract][Full Text] [Related]
35. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma.
Vora SR; Zheng H; Stadler ZK; Fuchs CS; Zhu AX
Oncologist; 2009 Jul; 14(7):717-25. PubMed ID: 19581525
[TBL] [Abstract][Full Text] [Related]
36. Alpha-fetoprotein normalization as a prognostic surrogate in small hepatocellular carcinoma after stereotactic body radiotherapy: a propensity score matching analysis.
Jung J; Yoon SM; Han S; Shim JH; Kim KM; Lim YS; Lee HC; Kim SY; Park JH; Kim JH
BMC Cancer; 2015 Dec; 15():987. PubMed ID: 26681337
[TBL] [Abstract][Full Text] [Related]
37. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
Xu S; Lai R; Zhao Q; Zhao P; Zhao R; Guo Z
Front Immunol; 2021; 12():794099. PubMed ID: 34950153
[TBL] [Abstract][Full Text] [Related]
38. Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma.
An HJ; Jang JW; Bae SH; Choi JY; Yoon SK; Lee MA; You YK; Kim DG; Jung ES
Liver Transpl; 2012 Dec; 18(12):1406-14. PubMed ID: 22821639
[TBL] [Abstract][Full Text] [Related]
39. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma.
Hashimoto K; Ikeda Y; Korenaga D; Tanoue K; Hamatake M; Kawasaki K; Yamaoka T; Iwatani Y; Akazawa K; Takenaka K
Cancer; 2005 May; 103(9):1856-64. PubMed ID: 15779015
[TBL] [Abstract][Full Text] [Related]
40. Early changes in immunoglobulin G levels during immune checkpoint inhibitor treatment are associated with survival in hepatocellular carcinoma patients.
Balcar L; Bauer D; Pomej K; Meischl T; Mandorfer M; Reiberger T; Trauner M; Scheiner B; Pinter M
PLoS One; 2023; 18(4):e0282680. PubMed ID: 37027398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
